Ionis Pharmaceuticals Drives 55% Q3 Revenue Growth, Eyes New RNA‑Therapeutic Breakthroughs
Ionis Pharma’s Q3 revenue jumps 55% to $243M as PRN‑200 drives sales, positioning the RNA‑therapy leader for future approvals and investor gains.
3 minutes to read


